EU/3/15/1558 - orphan designation for treatment for Ebola virus disease
three chimeric human/murine monoclonal antibodies against the Ebola (Zaire) surface glycoprotein (porgaviximab)
OrphanHuman
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
Overview
This medicine is now known as porgaviximab.
On 9 October 2015, orphan designation (EU/3/15/1558) was granted by the European Commission to Dr Stefan Blesse, Germany, for three chimeric human/murine monoclonal antibodies against the Ebola (Zaire) surface glycoprotein (also known as ZMapp) for the treatment for Ebola virus disease.
The sponsorship was transferred to Granzer Regulatory Consulting & Services in November 2019.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2021 on request of the Sponsor.
Ebola virus disease is a severe disease caused by infection with viruses known as ebolaviruses. There are 5 known species of ebolavirus, 4 of which are known to cause the disease in humans. Zaire ebolavirus, sometimes referred to simply as 'ebola virus' or EBOV, is the cause of the largest outbreaks of the disease to date and has led to the most deaths.
Infection is caused by contact with the body fluids of an infected person. After infection there is an incubation period of between 2 to 21 days, following which the newly infected person starts to experience symptoms. The first symptoms typically are fever, headache, fatigue, muscle pain and sore throat. These are followed by other symptoms such as diarrhoea, vomiting, rash, kidney and liver problems and, in some cases, internal bleeding and bleeding from the gums, eyes, nose and ears. Patients are infectious once they start develop symptoms.
Ebola virus disease is a life-threatening condition that is frequently fatal due to fluid loss and severe bleeding.
At the time of designation, Ebola virus disease affected less than 0.01 in 10,000 people in the European Union (EU). This is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
At the time of application for orphan designation, there were no satisfactory treatments authorised in the EU for treating Ebola virus disease. Different treatments were used to relieve the symptoms of the disease, such as providing fluids by a drip into a vein and balancing electrolytes (body salts), maintaining oxygen supply to the body and blood pressure, and treating other infections if they develop.
This medicine is made of 3 monoclonal antibodies (type of proteins) that have been designed to recognise and attach to different parts of a protein on the ebolavirus surface. By attaching to the virus, the antibodies are expected to neutralise its action.
The effects of the medicine have been evaluated in experimental models.
At the time of submission of the application for orphan designation, a clinical trial with the medicine in patients with Ebola virus disease was ongoing.
At the time of submission, the medicine was not authorised anywhere in the EU for Ebola virus disease. Orphan designation of the medicine had been granted in the United States for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 3 September 2015 recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- three chimeric human/murine monoclonal antibodies against the Ebola (Zaire) surface glycoprotein (porgaviximab)
- Intended use
- Treatment for Ebola virus disease
- Orphan designation status
- Withdrawn
- EU designation number
- EU/3/15/1558
- Date of designation
- Sponsor
Granzer Regulatory Consulting & Services
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: